Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Quick Facts
What This Study Found
Orforglipron, an oral non-peptide GLP-1 agonist, reduced HbA1c by up to 1.48 percentage points and body weight by up to 7.6% in early type 2 diabetes over 40 weeks in the ACHIEVE-1 phase 3 trial.
Key Numbers
559 participants, mean baseline HbA1c 8.0%. HbA1c change: -1.24% (3 mg), -1.47% (12 mg), -1.48% (36 mg) vs. -0.41% (placebo). All p < 0.001. Weight: -4.5% (3 mg), -5.8% (12 mg), -7.6% (36 mg) vs. -1.7% (placebo). Mean HbA1c at 40 weeks: 6.5-6.7%. Discontinuation 4.4-7.8% vs 1.4% placebo.
How They Did This
Phase 3, double-blind, placebo-controlled RCT (ACHIEVE-1, NCT05971940). 1:1:1:1 randomization to orforglipron 3, 12, or 36 mg or placebo daily for 40 weeks. Primary endpoint: HbA1c change.
Why This Research Matters
This is the first phase 3 trial confirming that a non-injectable, non-peptide GLP-1 drug can produce clinically meaningful blood sugar and weight improvements. It could dramatically expand access to GLP-1 therapy by eliminating the need for injections.
What This Study Doesn't Tell Us
No active comparator (injectable GLP-1 RA or oral semaglutide). 40-week duration. Patients with early T2D on diet/exercise only; may not represent broader population. GI adverse events higher with orforglipron.
Trust & Context
- Original Title:
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Published In:
- The New England journal of medicine, 393(11), 1065-1076 (2025)
- Authors:
- Rosenstock, Julio(10), Hsia, Stanley, Nevarez Ruiz, Luis, Eyde, Sarah, Cox, David, Wu, Wen-Shuo, Liu, Rong, Li, Jianghao, Fernández Landó, Laura, Denning, Max, Ludwig, Lisa, Chen, Yanyun
- Database ID:
- RPEP-13312
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13312APA
Rosenstock, Julio; Hsia, Stanley; Nevarez Ruiz, Luis; Eyde, Sarah; Cox, David; Wu, Wen-Shuo; Liu, Rong; Li, Jianghao; Fernández Landó, Laura; Denning, Max; Ludwig, Lisa; Chen, Yanyun. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.. The New England journal of medicine, 393(11), 1065-1076. https://doi.org/10.1056/NEJMoa2505669
MLA
Rosenstock, Julio, et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.." The New England journal of medicine, 2025. https://doi.org/10.1056/NEJMoa2505669
RethinkPeptides
RethinkPeptides Research Database. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist,..." RPEP-13312. Retrieved from https://rethinkpeptides.com/research/rosenstock-2025-orforglipron-an-oral-smallmolecule
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.